Prophylactic radiation for asymptomatic bone metastases may reduce pain and extend survival

Data from a randomized phase 2 trial—presented during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting—showed that prophylactic radiation therapy for high-risk, asymptomatic bone metastases in patients with solid tumors may reduce the incidence of skeletal-related events (SREs). After 1 year, SREs occurred in 1 of 62 lesions (1.6%) in those receiving RT, compared to 14 of 49 lesions (29%) for those receiving standard of care (P < .001).